Ardelyx Raises $30M
Fremont-based Ardelyx, a biopharmaceuticals firm developing treatments for irritable bowel syndrome, kidney disease, and diabetes, said Tuesday that it has raised $30M in a Series B funding round. The round included New Enterprise Associates, CMEA, Amgen Ventures, as well as individual investors. The firm said the funding will go towards advancing its pipeline. The firm is developing a non-absorbed, small molecule which operates on the intestines. The firm's lead compound is aimed at irritable bowel syndrome.
posted on Wednesday, August 31, 2011 (Link to more information)
Related companies:
ARDELYX, INC.
Related stories:
> Ardelyx Picks Up $110M In PIPE From Venture Investors
> Artimi Raises $26.5M
> Barosense Raises $27.4M
> Twitter Raises $200M
> Market6 Raises $5.5M
silicontap.com Home